The Diabetes Control and Complications Trials (DCCT) showed that intensive insulin treatment in type 1 diabetes reduced HbA1c by 2% (from 9% to 7%) over 6.5 years and lowered neuropathy incidence by 60%. The gene discussed is INS; the disease is diabetes mellitus.